Product Description
MYCO-006 is a short-acting MDMA analog being developed by Mydecine for eht treatment of stress disorders. (Sourced from: )
Mechanisms of Action: 5-HT2 Agonist
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mydecine
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Stress Disorders, Post-Traumatic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/28/2023 |
News Article |
Mydecine Announces Update Regarding the Special Access Program |
|
10/31/2023 |
News Article |
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements |
|
10/26/2023 |
News Article |
Mydecine Provides Q4 2023 Business Update |
|
10/10/2023 |
News Article |
Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings |